Tesofensine Research Guide

Full name: Tesofensine (Triple Monoamine Reuptake Inhibitor)

A triple monoamine reuptake inhibitor that blocks norepinephrine, serotonin, and dopamine reuptake, producing significant appetite suppression and increased metabolic rate.

How Tesofensine Works

Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis.

Dosing Protocol

• Typical dose: 0.25-0.5 mg
• Frequency: Once daily
• Duration: 24+ weeks
• Route: Oral

Reported Benefits

• Significant appetite reduction
• Increased metabolic rate
• Improved satiety signaling
• 10-12% body weight loss
• Oral administration convenience

Potential Side Effects

• Dry mouth
• Insomnia
• Increased heart rate
• Elevated blood pressure
• Constipation
• Mood changes

Research Citations

1. TEMPO Phase 2b: Tesofensine for obesity (2020) - Tesofensine 0.5mg produced 10.6% weight loss vs 2.0% placebo at 24 weeks.
2. Cardiovascular safety profile of tesofensine (2021) - Heart rate increases were dose-dependent and manageable at 0.25mg; blood pressure changes minimal.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• CagriSema - Full Profile
• Survodutide - Full Profile

View full Tesofensine profile with 3D molecule viewer →